What is Linagliptin? Linagliptin, marketed under trade name Tradjenta is a dipeptidyl peptidase-4 inhibitor developed by Boehringer Ingelheim for treatment of diabetes mellitus type 2. Taking this medicine along with adopting a healthy lifestyle can decrease your risk of developing serious or life-threatening complications, which may include heart disease, stroke, nerve damage, kidney problems, or eye problems.
- Adult dosage (ages 18-64 years). Take one 5-mg tablet, once daily.
- Child dosage (ages 0–17 years). This medication hasn’t been studied in children. It shouldn’t be used in people younger than 18 years.
- Senior dosage (ages 65 years and older). Your body may process this medication more slowly. Your doctor may monitor you closely to see whether you need a lowered dose because a regular adult dose may lower your blood sugar too much.